EZH2 and cancer: GSK2816126 is a highly selective and potent inhibitor of both wild type and mutant EZH2, decreases H3K27 tri-methylation, releases transcriptional repression of PRC2 target genes, and induces anti-proliferative activity in several wild type and mutant EZH2 cancer cell lines.